Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, also known as ALLHAT, was a randomized, double-blind, active-controlled study comparing at the same time, four different classes of antihypertensive drugs with the rate of coronary heart disease (CHD) events in ‘high-risk’ people with hypertension. Participants were initially randomised to chlorthalidone (diuretic) versus doxazosin (alpha-adrenergic blocker), lisinopril (ACE-inhibitor), and amlodipine (calcium channel blocker).[1]

Grade 1 hypertension

The doxazosin arm was discontinued early on in the trial because of a higher rate of combined cardiovascular events and admissions for heart failure compared with chlorthalidone. The study concluded that major CHD events did not differ between initial use of chlorthalidone versus lisinopril or amlodipine. As a result, the Joint National Committee (7) guidelines of 2003, recommended the cheaper but equally effective diuretics as a first line treatment for hypertension. The study also confirmed the previously held views that ACE inhibitors were less effective in blood pressure control and stroke prevention in men of African and Caribean descent.[1][2]

Background

By the mid-1990s, there was increasing awareness of the relative reduction of risks for stroke and CHD with lowering blood pressure, and the main drugs in use were initially diuretics and beta-blockers.[3] Shortly after, other newer classes of blood pressure lowering drugs were developed and the ALLHAT study aimed to clarify their relative values with the aim to also answer which one to use first.[1]

Design

In February 1994, initially 42,418 people, age over 55 years, with stage I or II hypertension or who were taking medication for high blood pressure were recruited across 623 centres in Canada, Puerto Rico, the US, and the US Virgin Islands. All had at least one other CHD risk factor including previous heart attack or stroke, electrocardiogram or echocardiogram verified left ventricular hypertrophy (LVH), a history of type II diabetes mellitus, current cigarette smoking, and low high-density lipoprotein cholesterol levels.[4] 35% were African American.[3] The doxazosin arm was discontinued in January 2000 because of a higher rate of combined cardiovascular events and admissions for heart failure compared with chlorthalidone. Follow-up of the remaining 33,357 participants was completed in 2002.[4]

Results

ALLHAT showed that major CHD events did not differ between initial use of chlorthalidone versus lisinopril or amlodipine. As diuretics proved equally effective and were cheaper, the Joint National Committee 7 guidelines of 2003, recommended diuretics as a first line treatment for hypertension. The study confirmed the previously held views that ACE inhibitors were less effective in blood pressure control and stroke prevention in men of African and Caribean descent. The study also revealed that calcium channel blockers did not cause higher rates of gastrointestinal bleeding or cancers and they were not less effective than other antihypertensives.[1].

References
  1. Myat, Aung; Gershlick, A. H.; Gershlick, Tony (2012). "17. Systemic arterial hypertension". Landmark Papers in Cardiovascular Medicine. Oxford: Oxford University Press. pp. 290–291. ISBN 978-0-19-959476-4. LCCN 2012940771.
  2. Bavry, Anthony A. (21 November 2016). "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial". American College of Cardiology. Retrieved 14 April 2020.
  3. Sica, Domenic A.; Carter, Barry I. (2013). "18. Diuretic therapy in cardiovascular disease". In Black, Henry R.; Elliott, William (eds.). Hypertension: A Companion to Braunwald's Heart Disease. Elsevier Health Sciences. p. 165. ISBN 978-1-4377-2766-1.
  4. Beevers, D. G.; Lee, K. W.; Lip, G. Y. H. (June 2003). "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?". Journal of Human Hypertension. 17 (6): 367–372. doi:10.1038/sj.jhh.1001556. ISSN 1476-5527.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.